Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

16 results about "Reading frame" patented technology

In molecular biology, a reading frame is a way of dividing the sequence of nucleotides in a nucleic acid (DNA or RNA) molecule into a set of consecutive, non-overlapping triplets. Where these triplets equate to amino acids or stop signals during translation, they are called codons.

Universal bacterial artificial chromosome recombinant virus transfer vector and construction method thereof

The invention belongs to the technical field of genetic engineering, and particularly relates to a universal bacterial artificial chromosome recombinant virus transfer vector and a construction method thereof, the transfer vector comprises a BAC amplification vector with pUC19-loxp-gpt-IRES-EGFP as a basic skeleton and pUC19-BAC as a functional sequence; according to the universal bacterial artificial chromosome recombinant virus transfer vector and the construction method thereof, a drug screening target gene reading frame and an EGFP fluorescent protein gene reading frame are connected through an IRES double-expression connection sequence, and double screening can be carried out; in the BAC construction process, screening genes and functional sequences are respectively constructed to a high-copy T vector, so that sufficient plasmid DNA can be conveniently copied and prepared. And through a proper restriction enzyme cutting site, introduction of various homologous arms is facilitated, the alignment is wide, simultaneous operation of various genomic sequences is facilitated, and the research efficiency is improved.
Owner:JINYU YOUBANG BIOTECHNOLOGY (JIANGSU) CO LTD

Methods of producing multimeric proteins in eukaryotic host cells

The present disclosure relates to the production of multimeric polypeptides (e.g., comprising two or more subunits, each subunit comprising two or more polypeptide chains, such as a multispecific or bispecific antibody) in eukaryotic host cells. In some embodiments, provided herein are methods for producing a multimeric polypeptide in a eukaryotic host cell using a host cell that comprises a polynucleotide comprising a translation initiation sequence operably linked to an open-reading frame encoding each polypeptide of the multimeric polypeptide. Advantageously, the present disclosure demonstrates that tuning the strength of the translation initiation sequences linked to each open-reading frame allows for higher production of the multimeric polypeptide with fewer incorrectly assembled side products. The present disclosure further provides cells, methods of screening, and kits related thereto.
Owner:GENENTECH INC

Recombinant plasmid and recombinant bacterium for producing nortetracycline as well as construction method and application of recombinant plasmid and recombinant bacterium

The invention relates to the technical field of synthetic biology, and discloses a recombinant plasmid and a recombinant bacterium for producing nortetracycline as well as a construction method and application of the recombinant plasmid and the recombinant bacterium. In order to heterologously produce the nortetracycline, the invention provides a recombinant plasmid for producing the nortetracycline, a starting plasmid of the recombinant plasmid is pOxy2, and the recombinant plasmid is obtained by knocking out oxyS and oxyR genes in the starting plasmid pOxy2, then knocking out oxyF genes and introducing ctcN and ctcM genes in an aureomycin biosynthesis pathway to the position of an oxyF original reading frame. The recombinant plasmid prepared by the invention is used for selecting a host which is rapid in growth and simple and convenient in genetic manipulation as a nortetracycline industrial production strain, so that biological synthesis of nortetracycline is realized, and no other tetracycline by-products exist.
Owner:INST OF MICROBIOLOGY CHINESE ACAD OF SCI

Therapeutic RNA

The present invention provides a modified therapeutic mRNA comprising at least one nucleic acid sequence selected from at least one frameshifted nucleic acid sequence, at least one ribosome slippery sequence, and / or at least one other reading frame sequence, wherein the nucleic acid sequence comprises at least one synonymous mutation. Also provided are methods for producing the modified therapeutic mRNA, methods for reducing off-target immunogenicity to the therapeutic mRNA, and methods for reducing out-of-frame translation and / or increasing the translational fidelity of the therapeutic mRNA. The modified therapeutic mRNA for use as a drug is further provided.
Owner:CAMBRIDGE ENTERPRISE LTD

Promoter and carrier composed of same and application thereof

An improved promoter and a use thereof. An improvement is to mutate a nucleic acid sequence between −35 region and −10 region in a promoter region into recognition sites for an endonuclease. The improvement can overcome the problem that a strong promoter in a vector based on blue-white screening initiates the transcription or translation of foreign genes and a transcription or translation product might be toxic to a host and cannot be cloned, avoid the deficiency that frameshift mutation of a gene due to a lack of 1-2 bp of the vector at digestion sites results in false positive clones, and eliminate a false negative phenomenon that a plate is rich in blue spots due to a small fragment of foreign DNA and a reading frame of the gene which is unchanged by inserting the foreign DNA.
Owner:AZENTA US INC

Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

The present invention is directed to a live-attenuated Mycobacterium tuberculosis composition comprising an isolated microorganism belonging to a M. tuberculosis MTBVAC strain having a i) PhoP-phenotype by the inactivation by a genetic deletion of the Rv0757 gene, wherein the open-reading frame (ORF) sequence of phoP consists of SEQ ID NO 4, and ii) the deletion of a second gene, Rv2930 (fadD26), that prevents PDIM production (PDIM-phenotype), wherein the open-reading frame (ORF) sequence of fadD26 consists of SEQ ID NO 2, for use in therapy in a human subject in need thereof, wherein the composition is administered to said subject via pulmonary delivery.
Owner:UNIV DE ZARAGOZA

Gene therapy for LEMD2 cardiomyopathy

PendingUS20260174900A1Peptide/protein ingredientsHydrolasesCardiac cellCells heart
Provided herein are composition and methods for gene therapy of LEM domain-containing protein 2 (LEMD2) cardiomyopathy. Viral vectors are used to deliver LEMD2 reading frame for gene augmentation in cardiac cells that harbor loss-of-function LEMD2 mutations. A murine model for LEMD2 cardiomyopathy is also described.
Owner:BOARD OF RGT THE UNIV OF TEXAS SYST

SmERF1B gene cloned in eggplant and application thereof

The invention relates to a SmERF1B gene cloned from eggplant and application of the SmERF1B gene in regulating and controlling the anthocyanin content of eggplant peel. The maximum reading frame sequence of the SmERF1B gene is represented by SEQ ID NO.1, and the amino acid sequence coded by the SmERF1B gene is represented by SEQ ID NO.2. The eggplant is transformed by adopting an agrobacterium tumefaciens-mediated method, and the result proves that compared with a non-transformed plant, the anthocyanin content in the peel of the transgenic eggplant is obviously increased, so that the color of the peel is darkened. The method is helpful for further understanding the eggplant peel coloring mechanism, so that the eggplant peel coloring can be regulated and controlled by utilizing a molecular means, and a new eggplant variety with high anthocyanin content is bred.
Owner:HUAIHUA UNIV

English combination reading frame

1. The name of the design product: English combination reading frame. 2. The use of the design product: for English teaching. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.
Owner:张颖

Method for screening and determining Duchenne muscular dystrophy exon jump splicing regulation sites

The invention provides a method for screening Duchenne muscular dystrophy exon jump splicing regulation sites, and particularly provides a method for screening potential gene editing sites for inducing exon jump based on mini genes. Potential gene editing sites capable of inducing all or part of exons to jump are screened based on mini-genes. The gRNA can be designed according to the sites, after the gRNA and editing tool enzyme are used together, mRNA which is slightly shortened but correct in reading frame can be generated, the mRNA can generate functional Dystrophin protein during expression, and normal functions of muscle cells are recovered, so that the DMD disease is treated.
Owner:SUZHOU GENASSIST THERAPEUTICS CO LTD

DNA constructs and nucleic acid compound tools

PendingCN122341745AStart codonDNA construct
This disclosure provides a DNA construct comprising: (a) a start exon encoding a start codon; (b) a first frameshift exon downstream of the start exon, the first frameshift exon including a first receptor splice site, wherein inclusion or exclusion of the first frameshift exon in alternative splicing determines the downstream reading frame of a mature mRNA transcript; and (c) a first specific exon downstream of the first frameshift exon, the first specific exon including a second receptor splice site, a first reporter gene, and a second reporter gene, wherein the first reporter gene is located upstream or downstream of the second reporter gene, and wherein the first reporter gene and the second reporter gene are in different reading frames, wherein exclusion of the first frameshift exon causes the first reporter gene to be in the same reading frame as the start codon, and wherein inclusion of the first frameshift exon causes the second reporter gene to be in the same reading frame as the start codon.
Owner:AGENCY FOR SCI TECH & RES

Method for screening and determining regulatory sites of exon skipping splicing in duchenne muscular dystrophy

PCT designated stageWO2026002227A1Organic active ingredientsHydrolasesDuchenne muscular dystrophyMedicine
The present invention provides a method for screening regulatory sites of exon skipping splicing in Duchenne muscular dystrophy. Specifically, the present invention provides a method for screening potential gene editing sites that induce exon skipping on the basis of mini-genes. The present invention screens potential gene editing sites that can induce all or part of exon skipping on the basis of mini-genes. gRNAs can be designed for these sites, and after these sites are used together with an editing tool enzyme, an mRNA that is slightly shortened but has a correct reading frame can be generated. Such an mRNA can produce a functional Dystrophin protein when expressed, and restore the normal function of muscle cells, thereby treating DMD disease.
Owner:SUZHOU GENASSIST THERAPEUTICS CO LTD

Raoultella ornitholytica antibacterial peptide and application thereof

The application belongs to the field of biomedicine and particularly relates to an ornithine-degrading Raoultella antibacterial peptide and application. The ornithine-degrading Raoultella antibacterial peptide is formed by a polypeptide (also referred to as antisense peptide) encoded by a complementary strand of a functional domain DNA sense strand in truncated CpxA in the same reading frame. The amino acid sequence of the ornithine-degrading Raoultella antibacterial peptide is shown as SEQ ID NO:2. The ornithine-degrading Raoultella antibacterial peptide and meropenem (MEM) jointly inhibit the growth of NDM-1 strain B1645-1B, has a very large application prospect, and provides a new drug for treating infectious diseases caused by ornithine-degrading Raoultella and solving drug resistance.
Owner:HUBEI UNIV OF MEDICINE

Method and system for analyzing hbv protein translation level based on ribo-seq

ActiveCN120950846BBiostatisticsSequence analysisReference genome sequenceNucleotide
The application provides a method and system for analyzing HBV protein translation level based on Ribo-seq, and belongs to the technical field of bioinformatics and virology. The method comprises the following steps: constructing a linear HBV reference genome sequence and optimizing the start point thereof; aligning Ribo-seq sequencing data to the linear HBV reference genome sequence to obtain P-site signals of each nucleotide position; separating the P-site signals according to reading frames to obtain signal intensity distribution of each reading frame; calculating the median signal density and signal leakage rate of the protein in the pure area of the HBV protein; correcting the observed signal of the target reading frame in the mixed area of the overlapping protein; and outputting the corrected translation signal intensity of the HBV protein. The method and system for analyzing HBV protein translation level based on Ribo-seq can accurately and quantitatively analyze the translation level of the HBV protein.
Owner:TIANJIN SECOND PEOPLES HOSPITAL

TtSIP1;2 gene and application thereof in improving plant tolerance

PendingCN122465944ABiotechnologyTransgene
This invention discloses a small basic membrane intrinsic protein TtSIP1;2 of mitochondrial aquaporin and its encoding gene. TtSIP1; 2 Its cDNA reading frame sequence is shown in SEQ ID NO.2, and the encoded amino acid sequence is shown in SEQ ID NO.1. This invention... TtSIP1;2 The gene-encoded protein TtSIP1;2 is associated with the tolerance of Saccharomyces cerevisiae to high salt, high osmotic pressure (simulated drought), high temperature, and H2O2 (oxidative stress). TtSIP1;2 The gene can enhance yeast's tolerance to various abiotic stresses, improve its survival rate under stress, and promote yeast vitality. Overexpression of this gene in Arabidopsis thaliana can improve the salt and drought tolerance of transgenic plants. This invention... TtSIP1;2 Genes can be applied to the genetic improvement of stress tolerance in engineered bacteria and plants, and can be used to cultivate transgenic engineered bacteria or plant varieties with improved tolerance to high salt, drought, high temperature and oxidative stress.
Owner:SOUTH CHINA BOTANICAL GARDEN CHINESE ACADEMY OF SCI

A nevus-like basal cell carcinoma syndrome gene mutation site and application thereof

ActiveCN120442782BDetermine pathogenicityExpanding the spectrum of disease-causing genesMicrobiological testing/measurementDNA/RNA fragmentationPrenatal diagnosisMedicine
The application provides a nevus basal cell carcinoma syndrome gene mutation site and application thereof, the gene mutation site is a frame shift mutation c.724_725delCA of a 5th exon of a PTCH1 gene, the mutation causes a subsequent codon reading frame change, and causes a PTCH1 protein frame shift mutation p.Q242Vfs*9.The c.724_725delCA mutation site of the application expands the pathogenic gene spectrum of NBCCS.The PTCH1 gene c.724_725delCA mutation in the application can be applied in NBCCS diagnosis, and a kit containing a mutation detection primer or probe and a genetic counseling and prenatal diagnosis method based on the mutation can be prepared.
Owner:CENT SOUTH UNIV